|
業務類別
|
Biotechnology |
|
業務概覽
|
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population. |
| 公司地址
| Talacker 35, Zurich, CHE, 8001 |
| 電話號碼
| +41 443858450 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.veraxa.com |
| 員工數量
| 3 |
| Dr. Heinz Schwer, PhD |
Chief Business Officer; Chief Business Officer and Managing Director of VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Mr. Torsten Buergermeister |
Chief Financial Officer of the Company and VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Dr. Rick Austin, PhD |
Chief Scientific Officer of VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Dr. Christoph Antz, PhD |
Chief Executive Officer of the Company and VERAXA Biotech GmbH |
-- |
19/02/2026 |
| Dr. Christoph Erkel, PhD |
Vice President and Head of Preclinical Development of VERAXA Biotech GmbH |
-- |
31/07/2025 |
|
|
| Mr. Oliver R. Baumann |
Chairman of the Board |
19/02/2026 |
| Mr. Marc Gruninger |
Independent Director |
19/02/2026 |
| Mr. Christoph Ziegler |
Independent Director |
19/02/2026 |
| Mr. David L. Deck |
Independent Director |
31/07/2025 |
| Dr. Warren Hosseinion, M.D. |
Independent Director |
19/02/2026 |
|
|
|
|
